Sign Out
Locally Advanced Non-small Cell Lung Cancer (NSCLC): IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable NSCLC whose disease has not progressed following definitive platinum-based chemoradiation therapy.
IMFINZI, in combination with tremelimumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Small Cell Lung Cancer (SCLC): IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Hepatocellular Carcinoma (HCC): IMFINZI in combination with tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
Biliary Tract Cancer (BTC): IMFINZI in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
